UroGen Pharma (URGN) Q1 2026 earnings review
J-Code Unlocks ZUSDURI Demand, Path to Profitability Clears
UroGen delivered a breakout quarter as the January 1st implementation of ZUSDURI's permanent J-code aggressively removed reimbursement bottlenecks. Total revenue surged 152% YoY to $51.0 million, effectively validating management's prior claims that early launch sluggishness was entirely logistical, not a lack of clinical demand. With ZUSDURI revenue jumping 109% sequentially to $29.2 million, it has already surpassed foundational product JELMYTO. Crucially, the company is demonstrating powerful operating leverage: while revenue more than doubled, operating expenses grew just 22%, halving the net loss YoY. If this ZUSDURI trajectory holds against the $240-250M FY26 OpEx guidance, the cash-burn narrative will rapidly shift to a profitability narrative.
🐂 Bull Case
The permanent J-code worked exactly as management predicted. ZUSDURI sales accelerated 109% sequentially, validating the $1B+ peak sales thesis as the drug successfully transitions to a primary, non-surgical treatment in recurrent LG-IR-NMIBC.
Despite heavily scaling the commercial team, Q1 net loss reversed sharply to -$23.6M from -$43.8M a year ago. Revenue is now growing vastly faster than costs.
🐻 Bear Case
SG&A expenses hit $51.5M in Q1, eating entirely through the $46.8M in gross profit. The commercial infrastructure requires sustained, massive ZUSDURI growth to reach actual breakeven.
Despite the massive beat, management still refuses to issue ZUSDURI revenue guidance, creating near-term modeling uncertainty in a high-beta biotech name.
⚖️ Verdict: 🟢🟢
Very Bullish. The central risk to the UroGen story over the last 6 months was whether ZUSDURI's slow start was due to a lack of demand or just reimbursement red tape. Q1 emphatically proved it was the latter. The commercial model is now validated.
Key Themes
ZUSDURI Adoption Accelerating Rapidly
The permanent J-code (J9282) effective January 1, 2026, unlocked pent-up demand. ZUSDURI revenue accelerated to $29.2M (up from $14.0M in Q4 2025 and $1.8M in Q3 2025). Key funnel metrics are highly supportive: the company reported 972 activated sites of care, 256 unique prescribers, and a critical core of 103 repeat prescribers. The mix of business is successfully pivoting into the community setting as reimbursement friction vanishes.
JELMYTO Provides Stable Baseline
JELMYTO revenue was stable at $21.7 million, representing a 7% YoY increase. While it is no longer the primary growth engine, it acts as a reliable funding source for the broader commercial infrastructure, generating consistent cash flow to partially offset the ZUSDURI launch burn.
Refusal to Guide ZUSDURI
Despite the parabolic revenue jump, management explicitly declined to provide full-year 2026 revenue guidance for ZUSDURI, citing the 'early stages of its commercial launch.' They intend to wait for at least two quarters of post-J-code data. This lack of quantitative goalposts forces the market to model blindly into H2 2026.
Future Product Cannibalization Strategy
UroGen plans to submit an NDA for UGN-103 (a next-gen mitomycin designed with faster manufacturing and easier reconstitution) in H2 2026. Management has previously stated their intent to rapidly transition the market from ZUSDURI to UGN-103 around 2028. While strategically sound to reset IP and improve logistics, managing inventory, physician re-education, and new J-codes for a product swap introduces medium-term execution risk.
SG&A Load Exceeds Gross Profit
While operating leverage is improving, the absolute cost base remains a concern. SG&A jumped 47% YoY to $51.5M due to the expanded ZUSDURI sales force and higher brand marketing. This single expense line consumed 110% of the quarter's total $46.8M gross profit. The company must maintain rapid sequential revenue growth to escape this cost overhang.
Other KPIs
Reversing. Down sharply from a net loss of $43.8 million in the prior year period. EPS improved to -$0.47 from -$0.92, directly demonstrating the path to profitability as the new revenue base scales over the fixed launch costs.
Decelerating. Decreased from $19.9 million in Q1 2025. The YoY drop is primarily due to base effects: Q1 2025 included the acquisition cost of UGN-501 and pre-approval ZUSDURI manufacturing costs.
Increased from $120.5 million at the end of FY25. The balance was replenished by a February 2026 debt refinancing with Pharmakon Advisors, replacing a $125M loan with a new $200M tranche at an 8.25% fixed rate, extending principal repayments out to 2030.
Guidance
Stable. Implies a 3% to 7% YoY growth rate over FY25's $94 million. This indicates management expects mature, steady demand without significant acceleration.
Accelerating slightly vs FY25 ($222.2M implied total). Includes $20M to $24M in non-cash share-based compensation. At the Q1 run-rate, OpEx is tracking slightly ahead of the $245M midpoint, suggesting spend may plateau or dip slightly in the back half of the year.
Key Questions
Community vs. Hospital Mix
With the permanent J-code now active, how has the ratio of ZUSDURI adoption between community urology practices and hospital outpatient settings shifted in Q1?
ZUSDURI Gross-to-Net
Now that ZUSDURI is transitioning to routine commercial volume via the J-code, what does the normalized gross-to-net discount profile look like, particularly regarding 340B exposure compared to JELMYTO?
Conditions for Guidance
You noted you are waiting for more data before providing ZUSDURI guidance. What specific KPI stability (e.g., patient conversion timelines, repeat prescriber velocity) are you looking for to issue formal numbers?